--- title: 'Life Sciences Daily Summary: What Happened on October 4, 2026' headline: AstraZeneca’s tozorakimab cut COPD exacerbations in two Phase 3 trials description: Bayer pledged $2.2 billion for a US manufacturing facility. url: https://thebench.bio/news/summaries/2026-10-04 topic: all date: '2026-10-04' covers: - '2026-10-04' date_published: '2026-10-05T05:45:48Z' date_modified: '2026-10-05T05:45:48Z' sources: 2 publisher: The Bench (thebench.bio) --- # Life Sciences Daily Summary: What Happened on October 4, 2026 **AstraZeneca’s tozorakimab cut COPD exacerbations in two Phase 3 trials** Bayer pledged $2.2 billion for a US manufacturing facility. ## Today in brief AstraZeneca said tozorakimab lowered moderate-to-severe COPD exacerbations by 30% in OBERON and 29% in TITANIA across current and former smokers. [1] Bayer pledged $2.2 billion for a manufacturing facility in the United States. [2] ## Tozorakimab reduced COPD exacerbations in two Phase 3 trials Among former smokers, exacerbation rates were 29% lower in OBERON and 34% lower in TITANIA with tozorakimab than with placebo. [1] The replicate, double-blind, placebo-controlled trials enrolled 2,306 symptomatic patients with a recent history of multiple moderate or at least one severe COPD exacerbation. [1] Participants received 300 mg of tozorakimab or placebo every four weeks for 52 weeks, alongside their regular inhaled maintenance treatment. [1] Across current and former smokers, rates fell 30% in OBERON and 29% in TITANIA compared with placebo. [1] A combined analysis found exacerbation rates fell 43% among patients with blood eosinophil counts of at least 300 cells per microliter, versus 23% among those below 150 cells per microliter. [1] Researchers ran the analysis of patients with counts of at least 150 cells per microliter after designing the trials. [1] AstraZeneca says tozorakimab is intended to block interleukin-33 signaling and address inflammation and mucus dysfunction. [1] Separate trials are studying tozorakimab in severe viral lower respiratory tract disease (Phase 3) and asthma (Phase 2). [1] The FDA has given tozorakimab Fast Track status for COPD and severe viral lower respiratory tract disease. [1] ## The day in numbers - **2,306**: Patients enrolled across the OBERON and TITANIA COPD trials. [1] - **$2.2 billion**: Bayer’s pledge for a US manufacturing facility. [2] ## Sources 1. [AstraZeneca’s tozorakimab cuts COPD exacerbations by up to 34% in phase 3 trials](), Pharmafile, 2026-10-04 2. [Bayer pledges $2.2bn to US manufacturing facility](), pharmaphorum, 2026-10-04 --- The Bench wrote this from the reporting cited above, with a language model drafting and editing. [1]: [2]: